Search

Multiple copies of a gene called YES1 appear to be responsible for certain precision drugs losing their effectiveness.

… Thursday, June 7, 2018 Summary A collaborative study between scientists at Memorial Sloan Kettering and the New York Genome Center has identified one way that lung cancer cells outsmart a common targeted drug therapy. The results, reported in the Proceedings of the National Academy of Sciences, pave

Radiologist and molecular imaging researcher Moritz Kircher was awarded a Brain and Immuno-Imaging Grant by The Dana Foundation. This three-year grant supports the development of a dual-modality MRI-Raman nanoparticle that allows combined pre-and intra-operative visualization of glioblastomas.

… Wednesday, November 30, 2011 Radiologist and molecular imaging researcher Moritz Kircher  was awarded a Brain and Immuno-Imaging Grant by The Dana Foundation. This three-year grant supports the development of a dual-modality MRI-Raman nanoparticle that allows combined pre-and intra-operative visualization

A surprising finding challenges long-held dogma about how certain immune cells develop into specialized types in diverse tissues.

… Thursday, September 8, 2016 Summary Macrophages are immune cells that exist in diverse forms in various tissues. They interact constantly with cancer cells and appear to both target them and assist them under different circumstances. A new finding sheds light on how macrophages develop into different

Learn about MSK's expertise and compassion in caring for people under 50 who are facing cancer.

… Friday, June 6, 2025 When 26-year-old Jo Luzarraga was diagnosed with breast cancer in Manila, Philippines, her older sister Jan Claire swung into action. “I told her, you’re moving to Queens, New York, to live with me and my daughter and my partner,” says Jan Claire, who is 40. “And you’re going to

Learn how rectal cancer patients with HER2 driven tumors benefited from an early stage clinical trial at MSK.

… Saturday, April 18, 2026 A clinical trial at Memorial Sloan Kettering Cancer Center (MSK) is showing promise for people with early-stage rectal cancer whose tumors are driven by excessive amounts of a protein called HER2 (human epidermal growth factor receptor 2). The trial suggests that many of these

Learn how MSK researchers are deploying mRNA vaccines against pancreatic cancer.

… Sunday, April 19, 2026 An experimental, individualized therapeutic cancer vaccine that uses messenger RNA (mRNA) to treat pancreatic cancer continues to show potential in a small patient group. Follow-up results from a phase 1 clinical trial show that nearly 90% of people whose immune systems responded